Verteporfin

Verteporfin

Verteporfin (IUPAC name: Porphyryl chloride, benzoporphyrin derivative) is a medication used in photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration (AMD), pathologic myopia, and ocular histoplasmosis. It is administered intravenously and activated by non-thermal red light in the presence of oxygen to generate reactive oxygen species, leading to the destruction of targeted cells.

Medical Uses

Verteporfin is primarily used in the treatment of neovascular (wet) age-related macular degeneration, a leading cause of vision loss in older adults. It is also indicated for the treatment of pathologic myopia and ocular histoplasmosis, conditions that can lead to the development of abnormal blood vessels in the eye.

Mechanism of Action

The mechanism of action of verteporfin involves its accumulation in abnormal blood vessels in the eye. When activated by light of a specific wavelength (689 nm), verteporfin produces reactive oxygen species that damage the endothelial cells of these blood vessels, leading to their closure. This process helps to prevent further leakage and bleeding from these vessels, which can lead to vision loss.

Administration

Verteporfin is administered through intravenous infusion over 10 minutes. Following the infusion, the eye is exposed to a non-thermal red light at a wavelength of 689 nm for about 83 seconds to activate the drug. This light activation step is crucial for the drug's therapeutic effect.

Side Effects

Common side effects of verteporfin therapy include injection site reactions, visual disturbances, and photosensitivity. Patients are advised to avoid direct sunlight and bright indoor light for at least 48 hours after treatment to minimize the risk of photosensitivity reactions.

Contraindications

Verteporfin is contraindicated in patients with porphyria or hypersensitivity to any component of the formulation. Caution is advised in patients with severe liver impairment.

Pharmacokinetics

After intravenous administration, verteporfin is rapidly taken up by the lipoproteins in the blood and transported to the target tissues. Its half-life is approximately 5 to 6 hours, and it is primarily eliminated through the liver.

History

Verteporfin was approved by the FDA in 2000 for the treatment of age-related macular degeneration. It was the first drug approved for use in photodynamic therapy for the eye.

Future Directions

Research is ongoing to explore the use of verteporfin in treating other conditions, including certain types of cancer, where its ability to target rapidly dividing cells could be beneficial.